IA
MLYS icon

IFP Advisors’s Mineralys Therapeutics MLYS Stock Holding History

IFP Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27 Hold
1
– – ﹤0.01% 5056
2026
Q1 		$27 Sell
1
-7
-88% -$205 ﹤0.01% 4900
2025
Q4 		$290 Buy
8
+6
+300% +$241 ﹤0.01% 4413
2025
Q3 		$76 Buy
+2
New +$43 ﹤0.01% 4587
2025
Q2 		– Hold
0
– – – 4349
2025
Q1 		– Hold
0
– – – 4103
2024
Q4 		– Hold
0
– – – 4420

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

IFP Advisors's MLYS Position: Q2 2026 in Review

IFP Advisors held its Mineralys Therapeutics (MLYS) position steady in Q2 2026 at 1 share worth $27. The position accounts for ﹤0.01% of the portfolio, ranked #5056.

IFP Advisors first reported a position in MLYS in Q3 2025 and has held it in 4 quarters since. The position peaked at $290 in Q4 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • IFP Advisors held 1 share of Mineralys Therapeutics worth $27 as of Q2 2026.
  • IFP Advisors left its Mineralys Therapeutics share count unchanged in Q2 2026.
  • Mineralys Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #5056 holding.
  • IFP Advisors first reported a position in Mineralys Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • IFP Advisors's Mineralys Therapeutics position peaked at $290 in Q4 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.